Sukjun Kim

Sch Biol Sci Seoul Natl Univ

关注

立即认领

关注

立即认领

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 43 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Inflamed Immune Phenotype Predicts Favorable Clinical Outcomes of Immune Checkpoint Inhibitor Therapy Across Multiple Cancer Types

Jeanne Shen,Yoon-La Choi,Taebum Lee,Hyojin Kim,Young Kwang Chae,Ben W. Dulken,Stephanie Bogdan,Maggie Huang,George A. Fisher,Sehhoon Park,Se-Hoon Lee,Jun-Eul Hwang,Jin-Haeng Chung,Leeseul Kim,Heon Song,Sergio Pereira,Seunghwan Shin,Yoojoo Lim,Chang Ho Ahn,Seulki Kim,Chiyoon Oum,Sukjun Kim,Gahee Park,Sanghoon Song,Wonkyung Jung,Seokhwi Kim,Yung-Jue Bang,Tony S. K. Mok,Siraj M. Ali,Chan-Young Ock

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2024）

引用0浏览0WOS引用

Supplementary Table S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Chang Gon Kim,Min Hee Hong,Dahee Kim,Brian Hyohyoung Lee,Hyunwook Kim,Chan-Young Ock,Geoffrey Kelly,Yoon Ji Bang,Gamin Kim,Jung Eun Lee,Chaeyeon Kim,Se-Heon Kim,Hyun Jun Hong,Young Min Park,Nam Suk Sim,Heejung Park,Jin Woo Park,Chang Geol Lee,Kyung Hwan Kim,Goeun Park,Inkyung Jung,Dawoon Han,Jong Hoon Kim,Junha Cha,Insuk Lee,Mingu Kang,Heon Song,Chiyoon Oum,Seulki Kim,Sukjun Kim,Yoojoo Lim,Seunghee Kim-Schulze,Miriam Merad,Sun Och Yoon,Hyun Je Kim,Yoon Woo Koh,Hye Ryun Kim

crossref（2024）

引用0浏览0引用

Supplementary Figure S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

引用0浏览0引用

Supplementary Figure S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

引用0浏览0引用

A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

引用0浏览0WOS引用

Supplementary Figure S6 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

引用0浏览0引用

Supplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

引用0浏览0引用

An Artificial Intelligence-Powered PD-L1 Combined Positive Score (CPS) Analyser in Urothelial Carcinoma Alleviating Interobserver and Intersite Variability

Kyu Sang Lee,Euno Choi,Soo Ick Cho,Seonwook Park,Jeongun Ryu,Aaron Valero Puche,Minuk Ma,Jongchan Park,Wonkyung Jung,Juneyoung Ro,Sukjun Kim,Gahee Park,Sanghoon Song,Chan-Young Ock,Gheeyoung Choe,Jeong Hwan Park

HISTOPATHOLOGYno. 1 (2024): 81-91

引用0浏览0WOS引用

Supplementary Figure S8 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

引用0浏览0引用

Supplementary Figure S5 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

引用0浏览0引用

加载更多

作者统计

#Papers: 43

#Citation: 653

H-Index: 6

G-Index: 10

Sociability: 5

Diversity: 1

Activity: 18

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn